Johnson & Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September Johnson & Johnson
Should Johnson & Johnson’s (JNJ) Leadership Shift in Innovative Medicine Require Action From Investors? simplywall.st
JNJ Stock Quote Price and Forecast CNN
J&J innovative medicine chief Jennifer Taubert to retire, handing reins to North America head Fierce Pharma
Johnson & Johnson Encyclopedia Britannica
Johnson & Johnson Names Tom Cavanaugh to Lead Innovative Medicine Business citybiz
Johnson & Johnson names new Innovative Medicine leader NJBIZ
Johnson & Johnson EVP Jennifer Taubert to Retire, Tom Cavanaugh Named Successor Contract Pharma
Kenvue misses quarterly estimates as inflation, tariffs squeeze margins Reuters
News | Johnson & Johnson signs industrial lease at business park near Jacksonville airport CoStar
Johnson & Johnson announces change in senior leadership role PMLiVE
$5.5B Talc Settlement Offer May End Baby Powder Lawsuits Mesothelioma Center
Johnson & Johnson offers $5.5bn to settle talc cancer lawsuits Al Jazeera
Tom Cavanaugh Appointed Head of J&J Innovative Medicine Healthcare Digital
Johnson & Johnson embarks on supply chain restructuring Supply Chain Dive
J&J pharma leader to retire; Krystal slumps on gene therapy miss BioPharma Dive
Johnson & Johnson offers up to $5.5 billion to settle baby powder cancer lawsuits CNN
Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System Johnson & Johnson
J&J reaches sweeping talc deal that could end decade of litigation Reuters
J&J lowers 2026 profit forecast on deal costs, sees further hit in 2027 Reuters
Johnson & Johnson to pay $5.5bn settlement in talc cancer lawsuit The Guardian
Johnson & Johnson offers $5.5 billion to settle talc lawsuits cbsnews.com
Johnson & Johnson agrees to $5.5B settlement to resolve ovarian cancer talc lawsuits Top Class Actions
Johnson & Johnson Talcum Powder Lawsuit Sokolove Law
Johnson & Johnson Agrees to Pay $5.5 Billion to Settle Talc Lawsuits WSJ
Johnson & Johnson Is Becoming A Narrower Company Than You Bought Trefis
Guggenheim raises Johnson & Johnson stock price target on new products By Investing.com Investing.com Canada
Former Novo Nordisk North America chief joins board of US biotech company medwatch.com
The $85 Billion Consolation Prize For JNJ Shareholders Trefis
Amid $55B US manufacturing push, J&J turns to streamlining its pharma supply chain BioSpace
The Market Is Flashing a Valuation Warning -- but History Shows These Stocks Can Handle the Turbulence The Motley Fool
Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset Business Wire
J&J quarterly earnings beat Wall Street estimates on strength of medicines unit CNBC
Johnson & Johnson commits to $55B, 4-year US investment plan Fox Business
J&J misses company expectations for cardiovascular in Q2 MedTech Dive
Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation Business Wire
Johnson & Johnson to pay $5.5B to resolve talc litigation MassDevice
Icotyde Has Only 90 Days of Sales History When Cavanaugh Takes J&J’s Helm Tech Times
Johnson & Johnson Just Got FDA Clearance for Its Surgical Robot, Hiked Its Dividend for the 64th Time, and Is Targeting $100 Billion in Revenue. But Here's What Investors Should Be Most Excited About The Motley Fool
Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation Business Wire